Health & SocialSkim2025-12-17

CDSCO Approves Dato-DXd for Breast Cancer

What Happened

The Central Drugs Standard Control Organisation (CDSCO) approved the import and marketing of Datopotamab Deruxtecan (Dato-DXd) on December 17, 2025. This drug is a specialized TROP2-directed antibody-drug conjugate (ADC) designed for treating patients with metastatic breast cancer.

Why It Matters

The approval introduces advanced precision oncology to India, offering a targeted treatment alternative for advanced breast cancer cases and strengthening the domestic healthcare toolkit against high-mortality non-communicable diseases.

Quick reference — brief coverage only.

Up next

What Happened

Why It Matters

India-Ethiopia Ties Elevated to Strategic Partnership